Drug intelligence / Profile preview

EG-018

Development stage: Preclinical
Lead developer: Enhanced Genomics
Administration: Intraperitoneal, Intravenous

Overview

EG-018 is a preclinical-stage therapeutic candidate being developed by Enhanced Genomics (formerly Enhanc3D Genomics) for the treatment of inflammatory bowel disease (IBD). The asset was identified using the company's proprietary 3D multi-omics platform, which maps three-dimensional genome folding and links non-coding genetic variants to disease-driving genes in relevant cell types. By translating disease-associated variant data into causal biology, Enhanced Genomics aims to develop EG-018 as a targeted, genetically validated therapy for IBD.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on EG-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-018.

Explore the full profile